Stanley Frankel

Stanley Frankel has a long history of work experience in the medical field. In 2009, they began working as an Adjunct Associate Professor of Medicine at Columbia University Medical Center. In 2010, they became the Vice President of Clinical Development at Micromet. In 2012, they became the Executive Director, Therapeutic Area Head, Oncology Early Development at Amgen. In 2015, they became the Corporate Vice President at Celgene. In 2019, they became the Senior Vice President, Cellular Therapy Development at Bristol-Myers Squibb. In 2021, they became the Chief Medical Officer at Cytovia Therapeutics, the Member of the Scientific Advisory Board at Immunai, and the Non Executive Director at Precision BioSciences, Inc. In 2022, they became the Independent Director at Myeloid Therapeutics. Currently, they are the Principal at Stanley R. Frankel, M.D.

Stanley Frankel received a Doctor of Medicine (MD) from Northwestern University - The Feinberg School of Medicine between 1980 and 1985. Stanley then attended Harvard University before returning to Northwestern University - The Feinberg School of Medicine to receive a second Doctor of Medicine (MD). In 1988, they obtained certification from the American Board of Internal Medicine.